

Liquid Biopsy: Tumorgenetik in Körperflüssigkeiten

Ursula Amstutz¹, Tobias Grob², Carlo Largiadè¹, Erik Vassella²

Referenzen

1. Pakkala, S. & Ramalingam, S. S. Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm. *Hematol. Oncol. Clin. North Am.* **31**, 83–99 (2017).
2. Gold, B., Cankovic, M., Furtado, L. V., Meier, F. & Gocke, C. D. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. *J Mol Diagn* **17**, 209–224 (2015).
3. Heitzer, E., Ulz, P. & Geigl, J. B. Circulating Tumor DNA as a Liquid Biopsy for Cancer. *Clin Chem* **61**, 112–123 (2014).
4. Gautschi, O., Aebi, S. & Heukamp, L. C. Successful AZD9291 Therapy Based on Circulating T790M. *J Thorac Oncol* **10**, e122–3 (2015).
5. Oxnard, G. R. *et al.* Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol* **34**, 3375–3382 (2016).
6. Oxnard, G. R. *et al.* Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. *Clinical Cancer Research* **20**, 1698–1705 (2014).
7. Newman, A. M. *et al.* An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat Med* **20**, 548–554 (2014).
8. Messaoudi, El, S., Rolet, F., Mouliere, F. & Thierry, A. R. Circulating cell free DNA: Preanalytical considerations. *Clin Chim Acta* **424**, 222–230 (2013).
9. Toro, P. V. *et al.* Clinical Biochemistry. *Clin Biochem* **48**, 993–998 (2015).
10. Newman, A. M. *et al.* Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat Biotechnol* **34**, 547–555 (2016).
11. Chabon, J. J. *et al.* Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun* **7**, 1–14 (2016).
12. Murtaza, M. *et al.* Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* **497**, 108–112 (2014).